Acumen Pharmaceuticals, Inc.
ABOS
$2.72
$0.041.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 20.53M | 118.93M | 124.21M | 106.62M | 93.80M |
| Gross Profit | -20.53M | -118.93M | -124.21M | -106.62M | -93.80M |
| SG&A Expenses | 18.95M | 19.30M | 19.78M | 20.00M | 20.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.83M | 138.23M | 143.98M | 126.61M | 114.02M |
| Operating Income | -123.83M | -138.23M | -143.98M | -126.61M | -114.02M |
| Income Before Tax | -121.34M | -133.35M | -136.67M | -116.25M | -102.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -121.34 | -133.35 | -136.67 | -116.25 | -102.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.34M | -133.35M | -136.67M | -116.25M | -102.33M |
| EBIT | -123.83M | -138.23M | -143.98M | -126.61M | -114.02M |
| EBITDA | -123.77M | -138.17M | -143.92M | -126.55M | -113.95M |
| EPS Basic | -2.00 | -2.21 | -2.27 | -1.93 | -1.70 |
| Normalized Basic EPS | -1.25 | -1.38 | -1.42 | -1.21 | -1.07 |
| EPS Diluted | -2.00 | -2.21 | -2.27 | -1.93 | -1.70 |
| Normalized Diluted EPS | -1.25 | -1.38 | -1.42 | -1.21 | -1.07 |
| Average Basic Shares Outstanding | 242.25M | 241.75M | 241.26M | 240.77M | 240.05M |
| Average Diluted Shares Outstanding | 242.25M | 241.75M | 241.26M | 240.77M | 240.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |